Approved Checkpoint Drugs in Oncology

While representing a relatively focused segment of the broader oncology pipeline, checkpoint therapies remain a critical and evolving area of immuno-oncology, with continued development activity and expanding clinical applications.

This Report Offers Insight Into:

• The Approved Checkpoint Landscape: A structured view of currently approved checkpoint drugs, including key targets and how dual‑checkpoint strategies are positioned across oncology.
• Leading Indications and Clinical Use: Insight into the tumor types and treatment settings where checkpoint inhibitor combinations are most actively used, and a review of their efficacy, durability and safety
• The Deal Landscape and Patent Activity: An overview of recent commercial activity alongside patent trends, highlighting emerging co‑targets and disease indications influencing future checkpoint development.